The global myasthenia gravis treatment market is anticipated to expand at a substantial CAGR during forecast period, between 2020 and 2027. Myasthenia gravis (MG) is a long term neuromuscular disease in which voluntary muscles easily become weak and tired owing to the problems associated with the contraction of muscles. This autoimmune disease causes weakness in the muscles that are responsible for functions such as breathing and moving parts of the body. Most of the cases of myasthenia gravis are mild, and life expectancy is normal. The symptoms of MG improve after resting and worsen with physical activity.
Symptoms of myasthenia gravis include ocular myasthenia, ptosis, diplopia, dysarthria, and difficulty in swallowing. No definite treatmentsare available for MG. However, treatments with cholinesterase inhibitors or immunosuppressant can help control the symptoms of MG. The cholinesterase inhibitors assist patients in improving communication between muscles and nerves. These inhibitors are effective in patients with mild symptoms of MG.
Market Trends, Drivers, Restraints, and Opportunities:
- Increase in per capita income across the globe and rise in healthcare expenditure are propelling the myasthenia gravis treatment market.
- Growth in the occurrence of MG globally and surge in the number of research & development activities are driving the market.
- High cost associated with the treatment of MG and side effects of intravenous immunoglobulin (IVIG) preparations including sudden cough, muscle cramps, flushing, nausea, vomiting, back/joint pain, chills, fever, chest pain, and wheezingare restraining the market growth.
- Increase in focus of governments in developing countries on improving healthcare infrastructure is likely to create opportunities in the IVIG treatments and monoclonal antibodies, thereby fueling the global market.
Scope of the report:
The report on myasthenia gravis treatmentmarket includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
|
Attributes
|
Details
|
|
Base Year
|
2019
|
|
Historic Data
|
2017–2018
|
|
Forecast Period
|
2020–2027
|
|
Regional Scope
|
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
|
|
Report Coverage
|
Market Scope, Analysis, Share, Competitive Analysis, Growth Facts, Restraints, Opportunities and Revenue Forecast
|
Myasthenia Gravis TreatmentMarket Segment Insights:
High demand for medication treatments drives segment growth
In terms of treatments, theglobal myasthenia gravis treatmentmarket can be categorizedas medication, surgery, and others.Medications include immunotherapies such as corticosteroids, Soliris (eculizumab), and immunosuppressive drugs such as Neoral/Sandimmune (cyclosporine) and Prograf (tacrolimus). The medication segment held a dominant share of the market, as medications can easily help manage the symptoms of MG and improvethe immune system.
Access to a large patient pool in hospitals fuels segment growth
On the basis of end-users, the market can be segregated into hospitals, clinics, and others. The hospitals segment is estimated to expand at a high CAGR during the forecast period due to the availability of advanced equipment for treating MG in hospital settings. Moreover, hospitals provide access to a large patient pool, and thus the number of patients visiting hospitals for diagnosis and treatment has increased in the last decade.
Retail pharmacies segment accounts for a dominant share of the market
Based on distribution channels, the market can be classifiedas hospital pharmacies, retail pharmacies, and e-commerce. The retail pharmaciessegment held a considerable share of the market. In retail pharmacies, pharmacists interact with the patients to provide targeted counseling. This results in a better experience for the customer, and hence most of the people tend to purchase their medications from retail pharmacies.
North America constitutes dominant share of the market
In terms of regions, the global myasthenia gravis treatment market can segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North Americaaccounts for a large share of the marketowing to rising healthcare expenditure, reimbursement policies, and growing research & development activities in the established R&D facilities. Moreover, increasing adoption of monoclonal antibodies and immunotherapies in the US is driving the growth of the market in North America.
Segments
By Treatments
- Medication
- Surgery
- Others
By End-users
By Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
By Regions
- North America
- Europe
- Latin America
- Asia Pacific
- Middle East & Africa
Competitive Landscape
Key players in the myasthenia gravis treatment market include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals, Plc., Novartis, Pfizer, Inc., AbbVie Inc., F.Hoffmann-La Roche AG, GlaxoSmithKline Plc., Bausch Health Companies Inc., Shire plc, UCB Pharma, Mitsubishi Tanabe Pharma, Immunovant, CuraVac, and AstellasPharma. Collaborations, mergers, acquisitions, agreements, and partnerships are some growth strategies adopted by these players to strengthen their geographical presence.
Request For Customization
Enquiry Before Buying
Speak With Analyst
